Alec Stranahan
Stock Analyst at B of A Securities
(0.60)
# 3,899
Out of 4,876 analysts
31
Total ratings
33.33%
Success rate
-30.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $16.80 | +150.00% | 1 | Mar 28, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $14 → $12 | $4.70 | +155.32% | 5 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Buy | $15 | $4.90 | +206.12% | 1 | Feb 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $6.47 | +286.40% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.26 | +773.02% | 1 | Jan 7, 2025 | |
| ERAS Erasca | Upgrades: Buy | $5 | $1.31 | +281.68% | 2 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $3.76 | +59.57% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.28 | +557.89% | 1 | Aug 8, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $48 → $55 | $36.91 | +49.01% | 3 | Jul 16, 2024 | |
| NVAX Novavax | Maintains: Neutral | $12 → $18 | $6.37 | +182.57% | 3 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $140 | $138.88 | +0.81% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $8.14 | +415.97% | 1 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $36.72 | -83.66% | 2 | Dec 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $60 → $5 | $1.25 | +300.00% | 1 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $46.98 | -4.21% | 1 | Dec 1, 2022 |
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $16.80
Upside: +150.00%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $4.70
Upside: +155.32%
Candel Therapeutics
Feb 7, 2025
Initiates: Buy
Price Target: $15
Current: $4.90
Upside: +206.12%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $6.47
Upside: +286.40%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.26
Upside: +773.02%
Erasca
Jan 7, 2025
Upgrades: Buy
Price Target: $5
Current: $1.31
Upside: +281.68%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $3.76
Upside: +59.57%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.28
Upside: +557.89%
Revolution Medicines
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $36.91
Upside: +49.01%
Novavax
Jun 14, 2024
Maintains: Neutral
Price Target: $12 → $18
Current: $6.37
Upside: +182.57%
May 25, 2023
Maintains: Buy
Price Target: $118 → $140
Current: $138.88
Upside: +0.81%
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $8.14
Upside: +415.97%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $36.72
Upside: -83.66%
Dec 2, 2022
Downgrades: Underperform
Price Target: $60 → $5
Current: $1.25
Upside: +300.00%
Dec 1, 2022
Initiates: Buy
Price Target: $45
Current: $46.98
Upside: -4.21%